Apolipoprotein E Alleles and Motor Signs in Older Adults with Alzheimer's Dementia
- PMID: 40943487
- PMCID: PMC12429426
- DOI: 10.3390/ijms26178562
Apolipoprotein E Alleles and Motor Signs in Older Adults with Alzheimer's Dementia
Abstract
We investigated associations between apolipoprotein E (APOE) alleles and motor manifestations in Alzheimer's dementia (AD) capitalizing on National Alzheimer's Coordinating Center data: the baseline evaluations of older adults (≥60 years) with a diagnosis of AD were analyzed. Those with a concomitant diagnosis Parkinson's disease or other parkinsonian syndrome, and those treated with anti-parkinsonian agents were excluded. Three APOE groups were formed: APOE2 (APOE2 carriers), APOE3 (APOE3/APOE3) and APOE4 (APOE4/APOE4, APOE4/APOE3). UPDRS-III was used to assess the presence or absence of motor signs in 9 domains. Adjusted binary logistic models featuring the three APOE groups as exposures and motor domains as outcomes were estimated. There were 389 individuals in the APOE2, 1799 in the APOE3 and 2791 in the APOE4 groups. Compared to the APOE2 group, individuals in the APOE4 group had lower odds of having at least one motor sign [0.64 (0.50-0.82)]. Among motor signs, rigidity [0.53 (0.34-0.81)], bradykinesia [0.56 (0.40-0.77)], impaired chair rise [0.54 (0.37-0.78)] and impaired posture-gait [0.54 (0.36, 0.81)] exhibited significant associations. Exploratory analyses featuring APOE genotypes suggested dose-response relationships for both APOE2 and APOE4. In conclusion, APOE2 confers a risk towards motor (mainly parkinsonian) signs in AD. APOE4 may have a protective effect.
Keywords: Alzheimer’s dementia; apolipoprotein E; bradykinesia; gait; motor signs; posture; rigidity; tremor.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Gharbi-Meliani A., Dugravot A., Sabia S., Regy M., Fayosse A., Schnitzler A., Kivimäki M., Singh-Manoux A., Dumurgier J. The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study. Alzheimer’s Res. Ther. 2021;13:5. doi: 10.1186/s13195-020-00740-0. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- P20 AG068053/AG/NIA NIH HHS/United States
- P30 AG066515/AG/NIA NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- P30 AG066508/AG/NIA NIH HHS/United States
- P30 AG066519/AG/NIA NIH HHS/United States
- P30 AG072973/AG/NIA NIH HHS/United States
- P30 AG066462/AG/NIA NIH HHS/United States
- P30 AG066530/AG/NIA NIH HHS/United States
- P30 AG066509/AG/NIA NIH HHS/United States
- P20 AG068077/AG/NIA NIH HHS/United States
- P30 AG066546/AG/NIA NIH HHS/United States
- P30 AG072972/AG/NIA NIH HHS/United States
- P30 AG072979/AG/NIA NIH HHS/United States
- P20 AG068082/AG/NIA NIH HHS/United States
- P30 AG072975/AG/NIA NIH HHS/United States
- P30 AG066444/AG/NIA NIH HHS/United States
- P30 AG066507/AG/NIA NIH HHS/United States
- P30 AG072946/AG/NIA NIH HHS/United States
- P30 AG066518/AG/NIA NIH HHS/United States
- P30 AG066511/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- P30 AG066512/AG/NIA NIH HHS/United States
- P30 AG072978/AG/NIA NIH HHS/United States
- P30 AG062429/AG/NIA NIH HHS/United States
- P30 AG062422/AG/NIA NIH HHS/United States
- R01 AG079280/AG/NIA NIH HHS/United States
- P30 AG072977/AG/NIA NIH HHS/United States
- P30 AG062677/AG/NIA NIH HHS/United States
- P20 AG068024/AG/NIA NIH HHS/United States
- P30 AG072958/AG/NIA NIH HHS/United States
- P30 AG062715/AG/NIA NIH HHS/United States
- P30 AG066506/AG/NIA NIH HHS/United States
- P30 AG066468/AG/NIA NIH HHS/United States
- P30 AG072976/AG/NIA NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
- P30 AG072931/AG/NIA NIH HHS/United States
- P30 AG066514/AG/NIA NIH HHS/United States
- P30 AG072959/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
